FARMACIA HOSPITALARIA最新文献

{"title":"[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence","authors":"Cayetano M. Hernández Marín , Emilio Monte-Boquet , José Luis Poveda Andrés","doi":"10.1016/j.farma.2024.08.009","DOIUrl":"10.1016/j.farma.2024.08.009","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324001442/pdfft?md5=ca5c49020421296cf8aaab96e04a8dc1&pid=1-s2.0-S1130634324001442-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142169072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Perceived quality of life in patients with psoriasis treated with interleukin 17 or 23 inhibitors","authors":"","doi":"10.1016/j.farma.2024.04.012","DOIUrl":"10.1016/j.farma.2024.04.012","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the effectiveness in terms of quality of life perceived by adult patients with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors and to identify associated factors.</p></div><div><h3>Method</h3><p>Cross-sectional observational study including adult patients diagnosed with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors for at least 12 or 16 weeks in follow-up, respectively.</p></div><div><h3>Results</h3><p>Forty-one patients were included: 65% male, median age 54 years (SD<!--> <!-->=<!--> <!-->13). The included patients were treated with ixekizumab 35%, guselkumab 25%, secukinumab 17.5%, brodalumab 15%, and risankizumab 7.5%.</p><p>Psoariasis area severity index (PASI) reduction was 94.6% (RIC 76.8–100%), DLQI of 1 (RIC 0–2.75), DLQI<!--> <!-->≤<!--> <!-->1 60%. The most affected health dimensions were symptoms and perceptions (57.5%), activities of daily living (27.5%), and discomfort caused with treatment (17.5%). No association was found between DLQI score &lt;<!--> <!-->1 and demographic, comorbidities, and treatment-related variables. The median PASI reduction in patients with DLQI<!--> <!-->&lt;<!--> <!-->1 was superior to patients with DLQI<!--> <!-->&gt;<!--> <!-->1 (100% vs 90.2%, <em>p</em> <!-->=<!--> <!-->.025).</p></div><div><h3>Conclusions</h3><p>Patients with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors achieve adequate therapeutic targets achieving the target set according to clinical practice guideline recommendations (score ≤<!--> <!-->1 on the DLQI questionnaire and 90–100% reduction in the PASI index) and in accordance with the results of recent meta-analyses and real-life studies.</p><p>A greater reduction of the PASI index is observed in the group reaching the quality of life target, there being the possibility of using patient-reported outcomes in the evaluation of treatment effectiveness.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000692/pdfft?md5=c83a88fa814a06d3c5c26e56b9c7af3c&pid=1-s2.0-S1130634324000692-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141427921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Digital health for promoting adherence to antiretroviral treatment in patients with HIV/AIDS: A meta-review","authors":"","doi":"10.1016/j.farma.2024.04.015","DOIUrl":"10.1016/j.farma.2024.04.015","url":null,"abstract":"<div><h3>Introduction</h3><p>Digital health or “e-health” is a set of applications based on information and communication technologies (ICTs) that can be used to promote self-care and medication adherence in patients with chronic diseases. The aim of this study was to carry out a review of systematic reviews (meta-review) on efficacy studies of e-health interventions to promote adherence to antiretroviral therapy (ART) in people living with HIV/AIDS.</p></div><div><h3>Methodology</h3><p>A review of systematic reviews (“meta-review”) was performed using the Medline-PubMed database on efficacy studies of e-health components to promote adherence to ART, in patients with HIV/AIDS, proposing a structured search strategy (PICO question). A selection process for systematic reviews was conducted based on inclusion and exclusion criteria. Subsequently, the corresponding data were extracted, and the analysis was accomplished in descriptive tables.</p></div><div><h3>Results</h3><p>A total of 29 systematic reviews were identified, from which 11 were selected. These reviews comprised 55 RCTs with different e-health interventions and enrolled a total of 15,311 HIV/AIDS patients. Studies included a total of 66 comparisons (experimental group vs. control group) in indirect adherence measurements based on different measurement techniques (36 statistically significant); 21 comparisons of viral load (VL) measurements (10 statistically significant); and 8 comparisons of CD4⁺ cell count measurements (3 statistically significant). m-Health was the most studied component followed by the telephone call and e-learning.</p></div><div><h3>Conclusion</h3><p>Evidence was found that supports that some e-health interventions are effective in promoting adherence to ART and improving health outcomes in patients with HIV/AIDS, although it is identified that more studies are needed for more robust evidence.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000722/pdfft?md5=2afc3511a746ca082b26765c183033af&pid=1-s2.0-S1130634324000722-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach","authors":"","doi":"10.1016/j.farma.2024.03.008","DOIUrl":"10.1016/j.farma.2024.03.008","url":null,"abstract":"<div><h3>Introduction</h3><p>The first targeted therapy in oncology, imatinib, revolutionized chronic myeloid leukemia (CML) treatment and spurred research in targeted therapies for various cancers. CML results from a chromosomal translocation, forming the BCR-ABL1 fusion gene. Asciminib has been recently approved for third-line refractory or intolerant patients. Treatment-free remission (TFR) is attainable with sustained deep molecular response (DMR) and this approach could be incorporated into pharmacoeconomic models.</p></div><div><h3>Aims</h3><p>To establish a cost-effectiveness model comparing asciminib to approved third-generation tyrosine kinase inhibitors (TKIs) (bosutinib and ponatinib) with a focus on achieving TFR. Additionally, the budgetary impact of incorporating asciminib as a therapeutic alternative is assessed.</p></div><div><h3>Methods</h3><p>This model is based on a Markov chain with 7 states. The condition for achieving TFR is to remain for 5 years in DMR state. Efficacy of the model was measured in QALYs, and the costs included in the base case analysis are based in Spain. A probabilistic (PSA) and deterministic analysis (DSA) were carried out to assess the variability of the model. There were achieved 2 independent models comparing asciminib vs bosutinib and asciminib vs ponatinib.</p></div><div><h3>Results</h3><p>Asciminib, when compared with ponatinib, is a cost-saving alternative, as efficacy is similar between alternatives, and asciminib have a lower cost of 30,275€. Asciminib showed 4.33 more QALYs and a higher cost (203,591€) than bosutinib, resulting in an ICER of €47,010.49 per QALY. PSA shows that the parameters with higher influence in the variability of the model were the probability of transitioning to BP and probabilities of achieving MMR and DMR. A one-way analysis reports that the drug cost has a higher influence on both models, and the discount rate significantly affects the asciminib vs bosutinib model.</p></div><div><h3>Conclusion</h3><p>Asciminib broadens therapeutic choices for patient’s refractory or intolerant to 2 prior lines of treatment in a cost-effectiveness manner. The costs of drugs significantly impact the overall cost of the disease, emphasizing the importance of the selected discount rates for each drug. Given the relatively low incidence of CML, the introduction of asciminib has a limited budgetary impact, warranting individualized decisions based on patient`s clinical characteristics.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000448/pdfft?md5=efd25b152e7814ecc9fbd11a117e6556&pid=1-s2.0-S1130634324000448-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] The role of artificial intelligence in scientific publishing: perspectives from hospital pharmacy","authors":"Vicente Gimeno-Ballester ,&nbsp;Cristina Trigo-Vicente","doi":"10.1016/j.farma.2024.07.009","DOIUrl":"10.1016/j.farma.2024.07.009","url":null,"abstract":"<div><p>The article examines the impact of artificial intelligence on scientific writing, with a particular focus on its application in hospital pharmacy. It analyses artificial intelligence tools that enhance information retrieval, literature analysis, writing quality, and manuscript drafting.</p><p>Chatbots like Consensus, along with platforms such as Scite and SciSpace, enable precise searches in scientific databases, providing evidence-based responses and references. SciSpace facilitates the generation of comparative tables and the formulation of queries regarding studies, while ResearchRabbit maps the scientific literature to identify trends. Tools like DeepL and ProWritingAid improve writing quality by correcting grammatical, stylistic, and plagiarism errors. A.R.I.A. enhances reference management, and Jenny AI assists in overcoming writer's block. Python libraries such as langchain enable advanced semantic searches and the creation of agents.</p><p>Despite their benefits, artificial intelligence raises ethical concerns including biases, misinformation, and plagiarism. The importance of responsible use and critical review by experts is emphasised. In hospital pharmacy, artificial intelligence can enhance efficiency and precision in research and scientific communication. Pharmacists can use these tools to stay updated, enhance the quality of their publications, optimise information management, and facilitate clinical decision-making.</p><p>In conclusion, artificial intelligence is a powerful tool for hospital pharmacy, provided it is used responsibly and ethically.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324001259/pdfft?md5=e9666bd66723a78c075bc52b8b3806af&pid=1-s2.0-S1130634324001259-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Pharmacological interaction between rifamycins and anticoagulants: Case report","authors":"","doi":"10.1016/j.farma.2024.04.018","DOIUrl":"10.1016/j.farma.2024.04.018","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000758/pdfft?md5=95d0cbb02d8ce2975b5de242ae5e3f7d&pid=1-s2.0-S1130634324000758-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141437663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interacción farmacológica entre rifamicinas y anticoagulantes: caso clínico","authors":"","doi":"10.1016/j.farma.2024.03.001","DOIUrl":"10.1016/j.farma.2024.03.001","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000382/pdfft?md5=362c2bed9c2026cb5e09ef5245eeffd1&pid=1-s2.0-S1130634324000382-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140319502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Pharmacist access and training process for residency in Hospital Pharmacy in Argentina","authors":"","doi":"10.1016/j.farma.2024.04.016","DOIUrl":"10.1016/j.farma.2024.04.016","url":null,"abstract":"<div><p>Hospital pharmacy worldwide has proven to be a crucial element in healthcare. In Latin America, it draws inspiration from 2 main models: United States, which promoted clinical pharmacy and later pharmaceutical care, and Spain, which shares similar healthcare practices and the added advantage of a common language. Both models influenced the implementation of hospital pharmacy residencies in Argentina since the 1980s.</p><p>Hospital pharmacy residencies in Argentina constitute a paid system of intensive postgraduate training on a full-time basis with exclusive dedication. They are carried out in 11 provinces across Argentina in services with recognized teaching experience. Currently, there are 46 locations with a total of 75 annual vacancies for applicants.</p><p>The objective of hospital pharmacy residencies is to train pharmaceutical professionals with the necessary competencies to ensure the care of patients through the optimization of the safe, effective, and efficient use of medications and healthcare products tailored to each patient's individual therapy.</p><p>Hospital pharmacy residencies have demonstrated that pharmacists acquire specialized training that can be decisive in influencing healthcare policies related to the safe use of medications and healthcare products. Therefore, actions to promote and encourage interest in this field among pharmaceutical professionals are necessary, involving scientific societies, universities, pharmaceutical associations, and the political sphere.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000734/pdfft?md5=bd5bce98027cd50afeaf9838f6db5fba&pid=1-s2.0-S1130634324000734-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141421318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ciberseguridad, una prioridad de los servicios de farmacia en la era de la inteligencia artificial","authors":"Cayetano M. Hernández Marín ,&nbsp;Emilio Monte-Boquet ,&nbsp;José Luis Poveda Andrés","doi":"10.1016/j.farma.2024.08.001","DOIUrl":"10.1016/j.farma.2024.08.001","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324001338/pdfft?md5=279590148e1809fb00994c379d74e970&pid=1-s2.0-S1130634324001338-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the safety of medication-use systems in hospital emergency services.","authors":"María José Otero, Montserrat Alonso Díez, Helena Esteban Cartelle, Sonia Jiménez Hernández, Iria Miguéns Blanco, Marisol Samartín Ucha, Rosario Santolaya Perrín, Jesús Ruiz Ramos","doi":"10.1016/j.farma.2024.07.007","DOIUrl":"https://doi.org/10.1016/j.farma.2024.07.007","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to assess the implementation of safe medication practices in hospital emergency services, in order to understand the points of greatest risk as well as the safety challenges faced by these departments, and to plan collaboratively improvement initiatives.</p><p><strong>Method: </strong>Multicentric and descriptive study based on completion of the \"Medication safety self-assessment of emergency services\" from 5/16/2023 to 11/16/2023, at voluntarily participating emergency services. The survey contained 93 items grouped into 10 key elements. Mean score and mean percentages based on the maximum possible values for the overall survey, for the key elements and for each individual item of evaluation, were assessed.</p><p><strong>Results: </strong>A total of 72 emergency services completed the questionnaire. The mean score obtained for the overall questionnaire was 428.3 points (51.1% of the maximum score). Results showed a large variation among the scores of the participating services (range: 164-620.5). Four key elements had values below 50%, corresponding to competence and training of professionals in safety practices (38.4%); incorporation of pharmacists in emergency departments (42.1%), availability and accessibility of information about patients (43.1%), and patient education (48.1%). The highest values corresponded to labeling, packaging, and naming of medications (69.2%) and communication of prescriptions and other medication information (64%). No differences were found between emergency services in the key elements according to the dependency or size of the hospital, or the type of service, except for the item referring to the incorporation of pharmacists in the emergency service, where differences were observed between hospitals with less than 200 beds (28.9%) and those with more than 500 (52.2%).</p><p><strong>Conclusion: </strong>The application of the specific self-assessment questionnaire has made it possible to identify safety practices that are insufficiently implemented into emergency services in our country and to identify critical points for improvement for which planning collaborative initiatives to reduce medication errors in these departments should become a priority.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}